{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055054","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.130405+00:00","generated_at":"2026-06-02T08:35:22.153659+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytokinetics opens enrollment in CEDAR-HCM trial of aficamten in pediatric obstructive HCM","bullets":["Initial cohort ~40 adolescents (12-17) with LVEF ≥60%, Valsalva LVOT-G ≥50 mmHg, NYHA ≥II.","Dosing starts at 5 mg once daily; up-titration at Wk2/4/6 to 10/15/20 mg based on Valsalva LVOT-G ≥30 mmHg and LVEF ≥55%.","Primary endpoint: change in Valsalva LVOT-G at Week 12; secondary endpoints include resting LVOT-G, NYHA class, PK, NT-proBNP, hs-cTnI.","Second cohort of ~8-10 patients aged 6-11 will open after data from ≥20 adolescents complete Week 12."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055054","json":"https://secwatch.observer/filing/0000950170-24-055054.json","markdown":"https://secwatch.observer/filing/0000950170-24-055054.md","text":"https://secwatch.observer/filing/0000950170-24-055054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024055054/0000950170-24-055054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024055054/cytk-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:35:22.153659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}